Susan Abushakra

2.3k total citations · 2 hit papers
42 papers, 1.6k citations indexed

About

Susan Abushakra is a scholar working on Physiology, Psychiatry and Mental health and Pharmacology. According to data from OpenAlex, Susan Abushakra has authored 42 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Physiology, 20 papers in Psychiatry and Mental health and 10 papers in Pharmacology. Recurrent topics in Susan Abushakra's work include Alzheimer's disease research and treatments (21 papers), Dementia and Cognitive Impairment Research (15 papers) and Cholinesterase and Neurodegenerative Diseases (10 papers). Susan Abushakra is often cited by papers focused on Alzheimer's disease research and treatments (21 papers), Dementia and Cognitive Impairment Research (15 papers) and Cholinesterase and Neurodegenerative Diseases (10 papers). Susan Abushakra collaborates with scholars based in United States, United Kingdom and Canada. Susan Abushakra's co-authors include Martin Tolar, Marwan N. Sabbagh, John A. Hey, Anton P. Porsteinsson, Aidan Power, Reisa A. Sperling, Elizabeth Loder, Yongxin Yu, Petr Kočiš and Stephen D. Silberstein and has published in prestigious journals such as Neurology, International Journal of Molecular Sciences and Journal of the American Academy of Dermatology.

In The Last Decade

Susan Abushakra

40 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Aducanumab, gantenerumab, BAN2401, and ALZ-801—the first wave of amyloid-targeting drugs for Alzheimer’s disease with potential for near term approval

2020 258 citations Martin Tolar, Susan Abushakra et al. Alzheimer s Research & Therapy profile →
Neurotoxic Soluble Amyloid Oligomers Drive Alzheimer’s Pathogenesis and Represent a Clinically Validated Target for Slowing Disease Progression

2021 145 citations Martin Tolar, John A. Hey et al. International Journal of Molecular Sciences profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Susan Abushakra United States	16	1.0k	460	447	320	232	42	1.6k
Robert Lai United Kingdom	25	1.6k 1.6×	614 1.3×	447 1.0×	675 2.1×	327 1.4×	61	2.7k
Emma L. Jones United Kingdom	7	929 0.9×	324 0.7×	353 0.8×	604 1.9×	170 0.7×	10	2.0k
Thomas J. Montine United States	24	1.4k 1.4×	330 0.7×	548 1.2×	774 2.4×	114 0.5×	37	2.9k
Gary Tong United States	19	862 0.8×	324 0.7×	354 0.8×	802 2.5×	147 0.6×	35	2.1k
Mirjana Babić Leko Croatia	19	728 0.7×	238 0.5×	184 0.4×	471 1.5×	79 0.3×	45	1.6k
Ghania Ait‐Ghezala United States	30	625 0.6×	220 0.5×	388 0.9×	722 2.3×	72 0.3×	60	1.9k
Samantha Budd Haeberlein United States	13	784 0.8×	360 0.8×	211 0.5×	271 0.8×	267 1.2×	40	1.1k
Michael Hüll Germany	18	744 0.7×	361 0.8×	236 0.5×	578 1.8×	127 0.5×	41	1.6k
Martin Tolar United States	17	1.1k 1.1×	494 1.1×	382 0.9×	465 1.5×	233 1.0×	33	1.7k
Taher Darreh‐Shori Sweden	31	886 0.9×	1.2k 2.7×	374 0.8×	757 2.4×	622 2.7×	75	2.4k

Countries citing papers authored by Susan Abushakra

Since Specialization

Citations

This map shows the geographic impact of Susan Abushakra's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Susan Abushakra with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Susan Abushakra more than expected).

Fields of papers citing papers by Susan Abushakra

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Susan Abushakra. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Susan Abushakra. The network helps show where Susan Abushakra may publish in the future.

Co-authorship network of co-authors of Susan Abushakra

This figure shows the co-authorship network connecting the top 25 collaborators of Susan Abushakra. A scholar is included among the top collaborators of Susan Abushakra based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Susan Abushakra. Susan Abushakra is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hey, John A., Yongxin Yu, Susan Abushakra, et al.. (2025). Clinical Pharmacokinetics of Oral ALZ-801/Valiltramiprosate in a 2-Year Phase 2 Trial of APOE4 Carriers with Early Alzheimer’s Disease. Clinical Pharmacokinetics. 64(3). 407–424. 1 indexed citations

Abushakra, Susan, Aidan Power, Anton P. Porsteinsson, et al.. (2025). Clinical Efficacy, Safety and Imaging Effects of Oral Valiltramiprosate in APOEε4/ε4 Homozygotes with Early Alzheimer’s Disease: Results of the Phase III, Randomized, Double-Blind, Placebo-Controlled, 78-Week APOLLOE4 Trial. Drugs. 85(11). 1455–1472.

Tolar, Martin, John A. Hey, Aidan Power, & Susan Abushakra. (2024). The Single Toxin Origin of Alzheimer’s Disease and Other Neurodegenerative Disorders Enables Targeted Approach to Treatment and Prevention. International Journal of Molecular Sciences. 25(5). 2727–2727. 12 indexed citations

Hey, John A., Susan Abushakra, Kaj Blennow, et al.. (2024). Effects of Oral ALZ-801/Valiltramiprosate on Plasma Biomarkers, Brain Hippocampal Volume, and Cognition: Results of 2-Year Single-Arm, Open-Label, Phase 2 Trial in APOE4 Carriers with Early Alzheimer’s Disease. Drugs. 84(7). 811–823. 15 indexed citations

Abushakra, Susan, Anton P. Porsteinsson, Marwan Sabbagh, et al.. (2024). APOLLOE4 Phase 3 study of oral ALZ‐801/valiltramiprosate in APOE ε4/ε4 homozygotes with early Alzheimer's disease: Trial design and baseline characteristics. Alzheimer s & Dementia Translational Research & Clinical Interventions. 10(3). e12498–e12498. 10 indexed citations

Hey, John A., Yongxin Yu, Susan Abushakra, et al.. (2024). Analysis of Cerebrospinal Fluid, Plasma β-Amyloid Biomarkers, and Cognition from a 2-Year Phase 2 Trial Evaluating Oral ALZ-801/Valiltramiprosate in APOE4 Carriers with Early Alzheimer’s Disease Using Quantitative Systems Pharmacology Model. Drugs. 84(7). 825–839. 5 indexed citations

Alam, Murad, et al.. (2023). Botulinum toxin type E associated with reduced itch and pain during wound healing and acute scar formation following excision and linear repair on the forehead: A randomized controlled trial. Journal of the American Academy of Dermatology. 89(6). 1317–1319. 3 indexed citations

Hey, John D., Susan Abushakra, Kaj Blennow, et al.. (2023). Effects of ALZ-801, an Oral Amyloid Oligomer Inhibitor, on Biomarkers of Alzheimer’s Disease (AD): 12-Month Results of Phase 2 Biomarker Study in Early AD (S26.007). Neurology. 100(17_supplement_2). 2 indexed citations

Tolar, Martin, John A. Hey, Aidan Power, & Susan Abushakra. (2021). Neurotoxic Soluble Amyloid Oligomers Drive Alzheimer’s Pathogenesis and Represent a Clinically Validated Target for Slowing Disease Progression. International Journal of Molecular Sciences. 22(12). 6355–6355. 145 indexed citations breakdown →

10.

Tolar, Martin, Susan Abushakra, John A. Hey, Anton P. Porsteinsson, & Marwan N. Sabbagh. (2020). Aducanumab, gantenerumab, BAN2401, and ALZ-801—the first wave of amyloid-targeting drugs for Alzheimer’s disease with potential for near term approval. Alzheimer s Research & Therapy. 12(1). 95–95. 258 indexed citations breakdown →

11.

Hey, John A., Petr Kočiš, Jakub Hort, et al.. (2018). Discovery and Identification of an Endogenous Metabolite of Tramiprosate and Its Prodrug ALZ-801 that Inhibits Beta Amyloid Oligomer Formation in the Human Brain. CNS Drugs. 32(9). 849–861. 47 indexed citations

12.

Dhawan, Sunil, et al.. (2018). Safety and Efficacy of EB-001, a Novel Type E Botulinum Toxin, in Subjects with Glabellar Frown Lines: Results of a Phase 2, Randomized, Placebo-Controlled, Ascending-Dose Study. Plastic & Reconstructive Surgery. 142(6). 847e–855e. 32 indexed citations

13.

Abushakra, Susan, Anton P. Porsteinsson, Philip Scheltens, et al.. (2017). CLINICAL EFFECTS OF TRAMIPROSATE IN APOE4/4 HOMOZYGOUS PATIENTS WITH MILD ALZHEIMER’S DISEASE SUGGEST DISEASE MODIFICATION POTENTIAL. The Journal of Prevention of Alzheimer s Disease. 4(3). 1–8. 61 indexed citations

14.

Hey, John A., Yongxin Yu, Mark Versavel, et al.. (2017). Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer’s Disease. Clinical Pharmacokinetics. 57(3). 315–333. 93 indexed citations

15.

Abushakra, Susan, Anton P. Porsteinsson, B. Vellas, et al.. (2016). CLINICAL BENEFITS OF TRAMIPROSATE IN ALZHEIMER’S DISEASE ARE ASSOCIATED WITH HIGHER NUMBER OF APOE4 ALLELES: THE “APOE4 GENE-DOSE EFFECT”. The Journal of Prevention of Alzheimer s Disease. 3(4). 1–10. 50 indexed citations

16.

Soto, M., Susan Abushakra, Jeffrey L. Cummings, et al.. (2015). PROGRESS IN TREATMENT DEVELOPMENT FOR NEUROPSYCHIATRIC SYMPTOMS IN ALZHEIMER’S DISEASE: FOCUS ON AGITATION AND AGGRESSION. A REPORT FROM THE EU/US/CTAD TASK FORCE. The Journal of Prevention of Alzheimer s Disease. 2(3). 1–6. 15 indexed citations

17.

Liang, Earvin, Pierre N. Tariot, Susan Abushakra, et al.. (2012). P4‐359: Effects of oral ELND005 (Scyllo‐inositol) on brain scyllo‐inositol and myo‐inositol levels: Spectroscopy results from a phase 2 study in MILD‐TO‐MODERATE Alzheimer's disease. Alzheimer s & Dementia. 8(4S_Part_21).

18.

Naumann, Markus, Alastair Carruthers, Jean Carruthers, et al.. (2010). Meta‐analysis of neutralizing antibody conversion with onabotulinumtoxinA (BOTOX®) across multiple indications. Movement Disorders. 25(13). 2211–2218. 109 indexed citations

19.

Loder, Elizabeth, et al.. (2005). Pain-free rates with zolmitriptan 2.5 mg ODT in the acute treatment of migraine: results of a large double-blind placebo-controlled trial. Current Medical Research and Opinion. 21(3). 381–389. 34 indexed citations

20.

Abushakra, Susan. (2002). Migraine: A Neuroinflammatory Disease?. Headache The Journal of Head and Face Pain. 42(8). 841–841. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact